Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer

Background: Immune checkpoint inhibitors (ICIs) emerged as the preferred therapy in advanced lung cancer, understanding the treatment- and immune-related adverse events of these drugs is of great significance for clinical practice. Materials and methods: PubMed, Embase, Cochrane library and major co...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Jun, Wang, Chengdi, Ren, Pengwei, Jiang, Yuting, Tian, Panwen, Li, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2020
Materias:
Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953488/
https://www.ncbi.nlm.nih.gov/pubmed/32315071
http://dx.doi.org/10.1042/BSR20192347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953488/
https://www.ncbi.nlm.nih.gov/pubmed/32315071
http://dx.doi.org/10.1042/BSR20192347

Ejemplares similares